eMed Surpasses $2 Billion Valuation with New Funding
Miami-based digital healthcare company eMed, specializing in GLP-1 treatments, has officially become a company worth over $2 billion. This news came after eMed completed a $200 million Series A funding round on March 26.
The funding round was led by AON Consulting, with notable investors including retired NFL quarterback Tom Brady, who recently joined as the company’s Chief Wellness Officer, and Linda Yaccarino, the former CEO of X and current CEO of eMed.
Brady expressed his confidence in eMed’s AI platform, saying, “I believe eMed’s empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula.” He chose to invest both his time and resources into the company because of this belief.
The new funding will help eMed enhance its AI platform and develop a fresh model aimed at reducing healthcare costs for employers, particularly concerning GLP-1 diabetes and weight loss drugs, which are the focus of the eMed website.
According to eMed, GLP-1 medications are the most sought-after workplace benefit, yet only 20% of companies currently provide this option. eMed is determined to change that. Their program boasts a member adherence rate of over 90%, which is more than double the industry average. Participants have reported an average weight loss of 21 pounds, with 99% seeing improvements in at least one vital health marker within a six-month period.
Linda Yaccarino stated, “This funding showcases eMed’s growth and positions us as the leading company for population health, helping employers tackle rising healthcare costs.”
In related news, a recent study highlighted that younger Americans are feeling the financial strain of healthcare costs the most. The “Healthcare on Hold” report revealed that one in four Gen Z consumers is skipping doctor visits due to budget concerns, even though they typically require less medical attention.
The report emphasized that while medical expenses are challenging for all age groups, the impact is especially felt by younger adults, who often delay treatment due to the financial pressure of out-of-pocket costs.
